Porcine Circovirus Type 2 Vaccines: Commercial Application and Research Advances

Jinshuo Guo; Lei Hou; Jianwei Zhou; Dedong Wang; Yongqiu Cui; Xufei Feng; Jue Liu

doi:10.3390/v14092005

Porcine Circovirus Type 2 Vaccines: Commercial Application and Research Advances

Viruses. 2022 Sep 10;14(9):2005. doi: 10.3390/v14092005.

Authors

Jinshuo Guo^{1

2}, Lei Hou^{1

2}, Jianwei Zhou^{1

2}, Dedong Wang^{1

2}, Yongqiu Cui^{1

2}, Xufei Feng^{1

2}, Jue Liu^{1

2}

Affiliations

¹ Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Yangzhou University, Yangzhou 225012, China.
² Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225012, China.

Abstract

Porcine circovirus type 2 (PCV2) infection can lead to porcine circovirus-associated disease (PCVAD), causing great economic losses to the global swine industry. Conventional vaccination programs are a major measure in the prevention and control of this disease. Currently, there are 5 commercially available PCV2 vaccines in the international market and 10 kinds commercially available PCV2 vaccines in the Chinese market that confer good efficacy against this virus by alleviating clinicopathological manifestations and enhancing growth performance in pigs. In addition, diverse experimental PCV2 vaccines with protective efficiency have been developed, including attenuated chimeric, nucleic acid, subunit, multivalent, and viral-vectored vaccines. These experimental vaccines have been shown to be relatively effective in improving the efficiency of pig production and simplifying prevention procedures. Adjuvants can be used to promote vaccines with higher protective immunity. Herein, we review the application of multiple commercial vaccines over the years and research advances in experimental vaccines, which provide the possibility for the development of superior vaccines to successfully prevent and control PCV2 infection in the future.

Keywords: PCV2; PCVAD; adjuvant; commercial vaccines; experimental vaccines; protective efficiency.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Viral
Circoviridae Infections* / prevention & control
Circoviridae Infections* / veterinary
Circovirus* / genetics
Nucleic Acids*
Swine
Swine Diseases*
Viral Vaccines*

Substances

Antibodies, Viral
Nucleic Acids
Viral Vaccines

Grants and funding

This research was funded by the Introduction Program of High-Level Innovation and Entrepreneurship Talents in Jiangsu Province and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).